Cita APA

Andreoli, M. T., Pinnolis, M., Kieser, T., Sun, J., & Andreoli, C. M. (2015). Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. Digit J Ophthalmol.

Citación estilo Chicago

Andreoli, Michael T., Michael Pinnolis, Troy Kieser, Jennifer Sun, y Christopher M. Andreoli. "Feasibility and Efficacy of a Mass Switch From Ranibizumab (Lucentis) to Bevacizumab (Avastin) for Treatment of Neovascular Age-related Macular Degeneration." Digit J Ophthalmol 2015.

Cita MLA

Andreoli, Michael T., et al. "Feasibility and Efficacy of a Mass Switch From Ranibizumab (Lucentis) to Bevacizumab (Avastin) for Treatment of Neovascular Age-related Macular Degeneration." Digit J Ophthalmol 2015.